Hogan Lovells Events | 13 - 14 January 2025

Fireside chats with Hogan Lovells during JPM 2025

We are pleased to invite you to the Hogan Lovells Life Sciences and Health Care Horizons fireside chat series at the Marriott Marquis San Francisco during the 43rd Annual J.P. Morgan Healthcare Conference.

Each fireside chat will help emerging companies spot ripe opportunities and potential pitfalls when preparing your investments for 2025 - helping you to understand and tackle the issues shaping the future of the industry, for your local market and globally.

Check out our full program below and register for the sessions that most interest you.

Program Agenda

Monday, 13 January | 11:00 a.m. PT

U.S. election impact on life sciences investments and M&A opportunities

In the wake of the 2024 U.S. elections, stakeholders in the life sciences and health care industry are intensely focused on the policy implications for global financial markets, investment strategies, and merger & acquisition (M&A) opportunities. Join leading experts from Hogan Lovells and Eliquent for an off-the-record conversation on the incoming Trump administration’s FDA priorities, leadership changes, and the key challenges ahead in areas like precision medicine, in vitro diagnostic regulations, onshoring of manufacturing, and more.

Monday, 13 January | 2:00 p.m. PT

AI Regulation Outlook: Navigating evolving frameworks in the EU, UK, and U.S.

In the EU, the AI Act has been approved, carrying significant implications for medical device, technology, and pharmaceutical firms. In the U.S., there is no comprehensive federal AI legislation, but at least 45 states have introduced bills that would regulate AI, with 31 having enacted such legislation. Meanwhile in the UK, the government has adopted an informal cross-sector, principles and outcome-based framework for regulating AI, requiring international firms to prepare for a patchwork of AI regulatory guidelines and enforcement.

In this fireside chat, we will explore artificial intelligence regulatory concepts for which companies must be prepared, including the AI applicability assessment, gap analysis, corporate governance and policies, operator analysis, the CE marking process, and research exemption analysis. Our expert panelists will consider the practical steps that life sciences and health care companies need to be taking now to ensure compliance and plan for the future of your business with rapidly-evolving AI regulatory paradigms.

Tuesday, 14 January | 9:00 a.m. PT

Women’s Breakfast

Join us for a dynamic conversation that celebrates and empowers women leaders in life sciences, women’s health, and entrepreneurship, which will bring together trailblazing women at the forefront of innovation, research, and business. This event offers a unique platform for networking, inspiration, and collaboration. Among other leaders, we will hear from:

Iron Health co-founder Stephanie Winans, who will shed light on women’s healthcare from the provider and patient perspectives, as well as her experience fundraising for women's health as a female founder.
Freya Biosciences CEO and co-founder Colleen Acosta, whose clinical-stage company is taking an innovative approach to women’s health, with microbial immunotherapies to regulate the immune system and inflammatory responses implicated in a number of indications including infertility and preterm birth.
Organon Head of innovation ecosystem integration Diana Torgersen, whose focus on innovation in women’s health incorporates lessons from her experience as a venture investor at Novo Holdings.

Panelist list:

Stephanie Winans, Iron Health, co-founder and CEO
Colleen Acosta, Freya Biosciences, CEO and co-founder
Diana Torgersen, Organon, head of innovation ecosystem integration
Kristin Connarn, Hogan Lovells

Tuesday, 14 January | 12:00 p.m. PT lunch, 12:30 p.m. PT discussion

Opportunities under the new administration for venture capital and private equity investing in emerging life sciences fields.

The outcome of the U.S. election has far-reaching implications for the global investment landscape, especially in the dynamic field of venture capital and early-stage investing. Panelists at this exclusive, closed-door, Q&A event will forecast how the Trump administration’s approach may spark a seismic paradigm shift in health policy, funding, and innovation, influencing everything from regulatory frameworks to investor sentiment. Attendees will learn about corporate venture funding structures, regulatory pathways, and reimbursement for early-stage drug products, including “healthspan” and preemptive medicines. Among other topics, we will discuss how:

potential appointments of Trump’s nominees – including Marty Makary, Dave Welton, and Dr. Mehmet Oz – could influence drug approval processes, vaccine development, and regulatory oversight.
venture capital funds are being set up in response to the potential appointment of RFK Jr. to lead HHS, and his “Make America Healthy Again” campaign, with a heightened focus on products like nutraceuticals, pre-disease assessment tools, and preventive treatments aiming to extend the average lifespan.
Dr. Jay Bhattacharya may reorient government spending as NIH Director, with an increased focus on research into the common origins of cancer, cardiovascular disease, inflammation, muscle structure, and the use of innovative biomarkers.
the new administration may be good news for preventative medicine sponsors, increasing their market potential and drawing investment.
new Congressional leaders – like Sen. Bill Cassidy (R-LA), incoming Chair of the Senate Health Committee, and Sen. Rand Paul (R-KY), the incoming chair of the Senate Homeland Security Committee – are significantly reshaping the scope of federal regulations in the post-Chevron era, including rules related to laboratory-developed tests (LDTs), data privacy, Orange Book patent listings, and more.

Back To Listing